With clinical trials nearing an end, non-clinical study reports finalised, the Quality and Chemistry and Manufacturing Controls (CMC) dossier nearing finalisation, planning and executing the new registration application is critical for the timely success of the product development programme.
Clients need the help of BlueReg to provide the expertise in registration strategy in the US or in Europe, to provide the manpower to produce high quality registration dossiers using our multidisciplinary team of regulatory affairs, scientific writing, and publishing, and to manage the submission process through to a successful conclusion.
In parallel, there is an opportunity take advantage of Early Patient Access programs particularly in France where a combination of patient exposure (under the nominative or cohort Temporary Authorisation for Use (ATU) process) and reimbursement is possible ahead of the formal Marketing Authorisation Application (MAA) approval. This can enable clients to reach the market many months in advance of receiving the MAA.
As there are a series of steps required prior to the point of even considering a new application in the US or EU it is important to be fully aware of the risks and mitigations associated with the submission process. It is also important to engage with BlueReg as soon as the interest in an Early Access Programme (EAP) is raised. The process of developing a dossier, the assessment process itself, and the orchestration of the EAP in conjunction with the full MAA must be well planned in order that the maximum value can be achieved. There are certain conditions associated with the programme that can make or break the opportunity for success.
Regulatory submission planning is a team effort with multiple inputs and stakeholders. It is preferable to develop regulatory submission strategy early and implement a tactical action plan to ensure that deliverables are met according to expectations. Early investment in time pays dividends in the overall time point as ensures all stakeholders are driving towards the same goals with the same set of assumptions. Flexibility in resource and budget allocation models means that the support provided to client projects can be tailored – we do not operate a ‘one size fits all’ approach. We recognise that there will be peaks and troughs in workload and this can be reflected in the contact time with the client organisation during period of agency dossier assessment or when waiting for clinical trial readouts.
Clients rely on our regulatory intelligence as well as the experience and expertise of our consultants for the success of their project. We can provide you with an end-to-end project plan to guide you from registration strategy through to authorisation and beyond. Some of the services we offer include:
Do you want to register your healthcare product in the United States or the European Union? BlueReg has a team whose expertise covers the entire development process, from concept to marketing authorization, on centralized and / or multinational projects. Our consultants have varied experience ranging from regulatory strategy to operational execution.
BlueReg is your strategic partner to meet your goals for all medicinal product registrations worldwide. BlueReg provides comprehensive regulatory affairs services, in global regulations and intelligence, across all regions of the world, supported by the expertise of our consultants and our international qualified partners.
BlueReg can be your preferred partner to support the registration of your medicinal product in Europe, in the US or in other worldwide countries. Our team of experts can also facilitate and guide clients through the process of formulating the roadmap, provide critical review of one or more elements of the roadmap, or provide hands on operational support through authoring some or all the components.
BlueReg consultants can help navigate FDA regulations and provide support and advice for all your project requirements
BlueReg has a dedicated team who cover the whole development process from concept to approval, on centralized or multi-national projects. Our consultants have diverse experience ranging from regulatory strategy to operational execution and full project management support will be provided.
BlueReg is your strategic partner to meet your goals for all medicinal product registrations worldwide. BlueReg provides comprehensive regulatory affairs services, in global regulations and intelligence, across all regions of the world
BlueReg is your strategic partner to meet your goals in publishing activities and regulatory submissions worldwide. BlueReg provides a broad range of services for electronic Submissions (eSubmissions). You can rely on the BlueReg experienced team and efficient use of publishing and formatting tools to prepare your dossiers/documents according to Health Authority requirements.
BlueReg provide flexible solutions for scientific writing covering all kinds of engagements or operational platforms to meet your company’s needs from product development, registration through to launch and product maintenance activities. Our team are experienced in writing clinical modules for submission in the EU and the US, PIPs, ODDs, INDs, IMPDs and IBs, as well as briefing packages for scientific advice. The team also manage Chemistry Manufacturing and Controls (CMC) writing for chemical and biological products.
BlueReg can collaborate with your experts to author, review and update your Common Technical Document (CTD) as required for new Marketing Authorisation Application (MAA) submissions or during the lifecycle of the medicinal product.
Our CMC Regulatory support services include everything from regulatory strategy and preparation of meetings with health authorities, assessment and preparation of regulatory documents, responses to agency questions, maintenance of products on market, regulatory compliance strategy worldwide and geographical roll out.
BlueReg can support you with a highly experienced team of professsionals in preparing and writing of your clinical study reports, supporting the redaction proposal and document package for submission to the EMA to comply with EMA policy 0070.